Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Jan
15
Today In Oncology
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease–Free Survival in Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer
Nivolumab Plus AVD Reduces Disease Progression Risk in Advanced Classical Hodgkin Lymphoma
WGS-Based Classifier Better Predicts HRD Across Cancer Types
ACS Report Shows 5-Year Survival Rate for All Cancers Combined Has Reached 70%
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo